Prosight Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-62,000
| Closed | -$7.14M | – | 43 |
|
|
2024
Q3 | $7.14M | Buy |
62,000
+35,000
| +130% | +$4.03M | 1.76% | 21 |
|
|
2024
Q2 | $3.72M | Sell |
27,000
-3,500
| -11% | -$482K | 1.11% | 26 |
|
|
2024
Q1 | $4.21M | Sell |
30,500
-5,400
| -15% | -$745K | 1.17% | 24 |
|
|
2023
Q4 | $4.73M | Sell |
35,900
-44,100
| -55% | -$5.81M | 1.9% | 15 |
|
|
2023
Q3 | $9M | Sell |
80,000
-90,000
| -53% | -$10.1M | 2.85% | 11 |
|
|
2023
Q2 | $16M | Buy |
170,000
+90,000
| +113% | +$8.49M | 4.69% | 9 |
|
|
2023
Q1 | $8.1M | Buy |
+80,000
| New | +$8.1M | 3.84% | 11 |
|